tiprankstipranks
Trending News
More News >

Amgen presents new interim results from the global Phase 3 DeLLphi-304 trial

Amgen (AMGN) announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA reduced the risk of death by 40% and significantly extended median overall survival by more than five months compared to standard-of-care chemotherapy in patients with small cell lung cancer who progressed on or after one line of platinum-based chemotherapy. The results will be presented at the 2025 American Society of Clinical Oncology Annual Meeting and have been published in The New England Journal of Medicine.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue